Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.
Beta cells
C-peptide
Interleukin-2
Treg
adolescents
aldesleukin
children
immunotherapy
type 1 diabetes
Journal
Wellcome open research
ISSN: 2398-502X
Titre abrégé: Wellcome Open Res
Pays: England
ID NLM: 101696457
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
10
03
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
14
5
2020
Statut:
epublish
Résumé
Type 1 diabetes is a common autoimmune disease due to destruction of pancreatic β cells, resulting in lifelong need for insulin. Evidence suggest that maintaining residual β-cell function can improve glucose control and reduce risk of hypoglycaemia and vascular complications. Non-clinical, preclinical and some preliminary clinical data suggest that low-dose interleukin-2 (IL-2) therapy could block pancreatic β cells destruction by increasing the number of functional regulatory T cells (Tregs) that inhibit islet-specific autoreactive effector T cells (Teffs). However, there is lack of data on the effect of low-dose IL-2 in newly diagnosed children and adolescents with T1D as well as lack of specific data on its potential effect on β-cell function. The '
Identifiants
pubmed: 32399500
doi: 10.12688/wellcomeopenres.15697.1
pmc: PMC7194454
doi:
Banques de données
figshare
['10.6084/m9.figshare.11932491.v1']
Types de publication
Journal Article
Langues
eng
Pagination
49Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright: © 2020 Marcovecchio ML et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
Nat Genet. 2009 Sep;41(9):1011-5
pubmed: 19701192
J Clin Oncol. 1999 Jul;17(7):2105-16
pubmed: 10561265
Diabet Med. 2015 Oct;32(10):1346-53
pubmed: 26172028
Diabetes Metab. 2012 Nov;38(5):387-91
pubmed: 22771204
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
PLoS Med. 2016 Oct 11;13(10):e1002139
pubmed: 27727279
Diabetes Care. 2003 Mar;26(3):832-6
pubmed: 12610045
Diabetologia. 2017 Oct;60(10):1839-1850
pubmed: 28770318
Nat Rev Immunol. 2015 May;15(5):283-94
pubmed: 25882245
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282826
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
JCI Insight. 2016 Nov 3;1(18):e89278
pubmed: 27812545
J Autoimmun. 2016 Jul;71:78-87
pubmed: 27133597
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Clin Cancer Res. 2014 Apr 15;20(8):2215-25
pubmed: 24573552
Ann Rheum Dis. 2016 Jul;75(7):1407-15
pubmed: 26324847
J Immunol. 2012 May 1;188(9):4644-53
pubmed: 22461703
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3350-3358
pubmed: 29860430
F1000Res. 2016 Jan 27;5:
pubmed: 26918165
J Autoimmun. 2015 Apr;58:48-58
pubmed: 25634360
Ann Rheum Dis. 2019 Feb;78(2):209-217
pubmed: 30472651
Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305
pubmed: 24622415
Diabetologia. 2019 Jan;62(1):28-32
pubmed: 30392045
N Engl J Med. 2011 Dec 1;365(22):2067-77
pubmed: 22129253
Nat Genet. 2007 Sep;39(9):1074-82
pubmed: 17676041
Blood. 2016 Jul 7;128(1):130-7
pubmed: 27073224
Immunity. 2010 Apr 23;32(4):457-67
pubmed: 20412756
Mol Ther. 2014 Jul;22(7):1388-1395
pubmed: 24686272
Diabetes. 2015 Jun;64(6):2172-83
pubmed: 25576057
N Engl J Med. 2009 Oct 15;361(16):1548-59
pubmed: 19828532
Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135
pubmed: 29999222
Lancet. 2018 Jun 16;391(10138):2449-2462
pubmed: 29916386
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
Nat Genet. 2007 Jul;39(7):857-64
pubmed: 17554260
JAMA Dermatol. 2014 Jul;150(7):748-51
pubmed: 24872229
Curr Diab Rep. 2018 Aug 30;18(10):90
pubmed: 30168021
Ann Rheum Dis. 2015 Apr;74(4):791-2
pubmed: 25609413
Clin Pharm. 1991 Feb;10(2):110-28
pubmed: 2009728
Clin Immunol. 2017 Jun;179:47-53
pubmed: 28232030
Immunopharmacology. 2000 Sep;49(3):419-23
pubmed: 10996039
Curr Diab Rep. 2016 Jun;16(6):46
pubmed: 27076179
Nat Med. 2016 Sep;22(9):991-3
pubmed: 27500725